Navigation Links
NovaBay(R) Presents Data Confirming Its Aganocide(R) Compounds Are Effective In Killing Bacteria That Have Developed Multidrug-Resistance
Date:9/14/2009

EMERYVILLE, Calif., Sept. 14 /PRNewswire-FirstCall/ -- NovaBay(R) Pharmaceuticals, Inc. (NYSE-AMEX: NBY) (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, presented in two poster sessions today at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. These two separate laboratory studies of its Aganocide(R) compounds reveal potent activity in killing bacteria that have developed resistance to antiseptics and antibiotics and that the compounds demonstrate rapid bactericidal and anti-biofilm activity in the presence of plasma, serum or albumin.

The two studies conducted by NovaBay scientists advance the company's efforts to provide solutions to the global problem of multidrug-resistant bacteria, which are rapidly diminishing the effectiveness of antibiotics and antiseptics for the treatment and prevention of many common infections. While multi-drug resistance to antibiotics has received much attention over the past few years, resistance to antiseptics is becoming an increasing concern.

"Modern medicine faces an urgent need to develop new classes of drugs that do not develop resistance to antibiotics and antiseptics," said Ron Najafi, president and CEO of NovaBay. "Our Aganocide compounds are an example of such a drug and they are on the bioequivalent of the natural anti-microbial compounds produced in white blood cells that have remained effective against invading pathogens for millions of years."

The first study examined the bactericidal activity of NovaBay's lead Aganoc
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
2. NovaBay(R) Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development
3. NovaBay(R) Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference September 10, 2009 in New York City
4. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
5. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
6. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
7. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
8. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
9. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
10. Arpida Presents Preclinical Data on AR-2474 at ICAAC
11. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... (PRWEB) August 29, 2014 The ... $5.6 billion in 2019. It is expected to ... to 2019, and was valued at $1.8 billion ... by Transparency Market Research. , For more information ... http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, titled “Companion ...
(Date:8/29/2014)... Local veterinarian, Dr. Keith Clement, and ... candidates to participate in an investigational study of donor ... goal of this study is to determine if a ... two arthritically affected joints can help reduce pain and ... the current investigational study must be older than nine ...
(Date:8/29/2014)... TX (PRWEB) August 29, 2014 ... ISO 13485:2003 certified, GAMP® 5 compliant imaging core ... an international Phase II clinical trial to assess ... , Throughout this trial, Intrinsic Imaging will provide ... limited to, protocol and charter development, site qualification, ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and provides ... ppb,” said Mark Tess, PhD, Mycotoxin Product Manager for Charm ... and USDA-GIPSA inspection agencies that have a need to detect ... in a matter of minutes with nothing but our equipment ... and grain before accepting it, but they no longer have ...
Breaking Biology Technology:Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... Inc. (Nasdaq: SRLS ) will release its fiscal ... on Friday, February 11, 2011. SeraCare executives will host a ... day to review first quarter results. The ... can be accessed by logging on to the "Investor Center, ...
... Inc. (Nasdaq: PCYC ) today reported recent ... that ended December 31, 2010.Recent Developments & Highlights ... PCI-32765 in B-cell malignanciesPharmacyclics has designed a broad Phase ... and diffuse large B-cell lymphoma to inform the Phase ...
... new way of splitting layered materials to give atom ... a range of novel two-dimensional nanomaterials with chemical and ... electronic and energy storage technologies. The collaborative* international ... Nanostructures and Nanodevices (CRANN), Trinity College Dublin, Ireland, and ...
Cached Biology Technology:Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 2Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 3Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 4Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 5Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 6Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 7Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 8Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 9New nanomaterials unlock new electronic and energy technologies 2
(Date:8/29/2014)... Boulder, Colo., USA - The rise of the Tibetan ... on Earth -- is important for both its profound ... In this study published in GSA Bulletin , ... -- "clumped" isotope thermometry -- using modern and fossil ... Zhada basin in southwestern Tibet. , Views range ...
(Date:8/28/2014)... pleased to announce the selection of Dr. Fred Baxendale ... acknowledges those who have served ESA for at least ... the Society that has reached an extraordinary level. Candidates ... Board and then voted on by the ESA membership. ... at Entomology 2014, ESA,s Annual Meeting in Portland, Oregon ...
(Date:8/28/2014)... an expansion of marine protected areas is needed to ... According to investigators from the Wildlife Conservation Society and ... on saving the largest numbers of species, often at ... difficult-to-replace ecological functions. , Many vital ecological ... that also are food for millions of people. ...
Breaking Biology News(10 mins):Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7Fred Baxendale selected as Honorary Member of the Entomological Society of America 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2
... Nov. 14, 2013  Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) ... J. Joseph Kim , has been selected to receive ... from the Korean American Society in Biotech and Pharmaceuticals ... of drug discovery and development through collaborations and information ...
... which fills in a significant gap in the fossil record ... today. A skull from the new species, named Panthera ... Jack Tseng a PhD student at the USC Dornsife College ... and now a postdoctoral fellow at the American Museum of Natural ...
... UC San Diego and their colleagues are unraveling the ... dazzling bioluminescent display in the form of puffs of ... world in muddy environments, from shallow bays to deeper ... marine wormcommonly known as the "parchment tube worm" due ...
Cached Biology News:Inovio Pharmaceuticals CEO Receives 2013 Drug Discovery & Achievement Award 2Inovio Pharmaceuticals CEO Receives 2013 Drug Discovery & Achievement Award 3Inovio Pharmaceuticals CEO Receives 2013 Drug Discovery & Achievement Award 4Inovio Pharmaceuticals CEO Receives 2013 Drug Discovery & Achievement Award 5Fossil of new big cat species discovered; oldest ever found 2Nature's glowing slime: Scientists peek into hidden sea worm's light 2Nature's glowing slime: Scientists peek into hidden sea worm's light 3
RABBIT ANTI NEOPTERIN...
... Beagle Serum • Beagle serum is collected ... one year of age Available Anticoagulants: ... (Na) N-06: K2EDTA N-08: ... N-03: Alsevers N-05: ACD ...
Collected from normal, healthy animals in carefully maintained standing herds of US orgin. Pricing: $45/unit for 1 - 10 units...
Ready-to-use; 40mg/ml X-Gal and 32mg/ml IPTG...
Biology Products: